Relay Therapeutics, Inc. (RLAY)
After hours:
| Previous close | 20.70 |
| Open | 20.29 |
| Bid | 20.12 x 1400 |
| Ask | 22.92 x 800 |
| Day's range | 19.63 - 21.40 |
| 52-week range | 12.65 - 38.15 |
| Volume | |
| Avg. volume | 1,011,564 |
| Market cap | 2.266B |
| Beta (5Y monthly) | 1.44 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -2.84 |
| Earnings date | 23 Mar 2022 - 28 Mar 2022 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 38.88 |
- GlobeNewswire
Relay Therapeutics Reports Second Quarter 2022 Financial Results and Corporate Highlights
Appointment of Sekar Kathiresan, M.D., CEO of Verve Therapeutics, to board of directors Disclosed three new programs from a growing breast cancer portfolio and a regulatory update on RLY-4008 at June 27th analyst and investor event CAMBRIDGE, Mass., Aug. 04, 2022 (GLOBE NEWSWIRE) -- Relay Therapeutics, Inc. (Nasdaq: RLAY), a clinical-stage precision medicine company transforming the drug discovery process by combining leading-edge computational and experimental technologies, today reported secon
- GlobeNewswire
Relay Therapeutics to Announce Second Quarter 2022 Financial Results and Corporate Highlights
CAMBRIDGE, Mass., July 28, 2022 (GLOBE NEWSWIRE) -- Relay Therapeutics, Inc. (Nasdaq: RLAY), a clinical-stage precision medicine company transforming the drug discovery process by combining leading-edge computational and experimental technologies, plans to report second quarter 2022 financial results and corporate highlights after the close of market on Thursday, August 4, 2022. The company will not be conducting a teleconference in conjunction with its financial results press release. About Rel
- GlobeNewswire
Relay Therapeutics Discloses Anticipated Registrational Path for RLY-4008 in Cholangiocarcinoma and Growing Breast Cancer Franchise at Virtual Analyst and Investor Event
End-of-phase 1 meeting with the U.S. Food and Drug Administration (FDA) resulted in alignment on the design of a single arm trial for pan-FGFR (FGFRi) treatment-naïve FGFR2-fusion cholangiocarcinoma (CCA) to potentially support accelerated approval Interim data from the once daily (QD) dosing schedule shared with the FDA demonstrated confirmed partial responses in eight out of thirteen (62%) FGFRi-naïve FGFR2-fusion CCA patients, including all four of the patients treated at the registrational t
